Michael Narkewicz
Concepts (606)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Diseases | 27 | 2026 | 304 | 5.910 |
Why?
| | Cystic Fibrosis | 38 | 2026 | 1158 | 5.790 |
Why?
| | Liver Cirrhosis | 18 | 2023 | 288 | 3.010 |
Why?
| | Elasticity Imaging Techniques | 7 | 2024 | 56 | 2.750 |
Why?
| | Liver | 40 | 2026 | 1887 | 2.360 |
Why?
| | Hepatitis C, Chronic | 18 | 2024 | 152 | 2.110 |
Why?
| | Liver Failure, Acute | 13 | 2018 | 67 | 2.060 |
Why?
| | Pyrrolidines | 9 | 2026 | 125 | 1.870 |
Why?
| | Hypertension, Portal | 9 | 2023 | 66 | 1.840 |
Why?
| | Benzodioxoles | 8 | 2026 | 158 | 1.730 |
Why?
| | Aminophenols | 8 | 2026 | 201 | 1.650 |
Why?
| | Liver Transplantation | 27 | 2023 | 823 | 1.630 |
Why?
| | Quinolones | 8 | 2026 | 201 | 1.510 |
Why?
| | Pyrazoles | 8 | 2026 | 509 | 1.380 |
Why?
| | Indoles | 8 | 2026 | 501 | 1.360 |
Why?
| | Antiviral Agents | 17 | 2024 | 767 | 1.290 |
Why?
| | Gastroenterology | 7 | 2024 | 189 | 1.230 |
Why?
| | Pyridines | 8 | 2026 | 605 | 1.210 |
Why?
| | Interferon-alpha | 13 | 2013 | 197 | 1.150 |
Why?
| | Child | 92 | 2026 | 22633 | 1.050 |
Why?
| | Biliary Atresia | 9 | 2015 | 158 | 0.980 |
Why?
| | Chloride Channel Agonists | 8 | 2026 | 109 | 0.840 |
Why?
| | Child, Preschool | 66 | 2024 | 11787 | 0.820 |
Why?
| | Drug Combinations | 10 | 2026 | 390 | 0.770 |
Why?
| | Serine | 7 | 2002 | 145 | 0.760 |
Why?
| | Fontan Procedure | 3 | 2018 | 191 | 0.740 |
Why?
| | Ribavirin | 8 | 2020 | 80 | 0.740 |
Why?
| | Pancreatitis | 3 | 2020 | 145 | 0.720 |
Why?
| | Lymphoproliferative Disorders | 3 | 2013 | 57 | 0.720 |
Why?
| | Epstein-Barr Virus Infections | 4 | 2013 | 101 | 0.700 |
Why?
| | Esophageal Stenosis | 2 | 2018 | 57 | 0.680 |
Why?
| | Ursodeoxycholic Acid | 3 | 2016 | 17 | 0.660 |
Why?
| | Alanine Transaminase | 6 | 2016 | 151 | 0.660 |
Why?
| | gamma-Glutamyltransferase | 5 | 2016 | 42 | 0.650 |
Why?
| | Cholestasis | 8 | 2026 | 219 | 0.640 |
Why?
| | Adolescent | 63 | 2026 | 22428 | 0.630 |
Why?
| | Humans | 134 | 2026 | 144759 | 0.630 |
Why?
| | Pancreatitis, Chronic | 2 | 2020 | 63 | 0.620 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 8 | 2026 | 370 | 0.620 |
Why?
| | Liver Function Tests | 7 | 2016 | 106 | 0.600 |
Why?
| | Aspartate Aminotransferases | 3 | 2016 | 85 | 0.600 |
Why?
| | Bile Ducts | 3 | 2013 | 67 | 0.570 |
Why?
| | Feces | 4 | 2026 | 513 | 0.570 |
Why?
| | Platelet Count | 3 | 2024 | 96 | 0.550 |
Why?
| | Esophageal and Gastric Varices | 5 | 2022 | 36 | 0.540 |
Why?
| | Female | 97 | 2026 | 78271 | 0.540 |
Why?
| | Hepacivirus | 8 | 2024 | 243 | 0.530 |
Why?
| | Infant | 46 | 2019 | 10034 | 0.530 |
Why?
| | Hepatitis, Autoimmune | 1 | 2017 | 13 | 0.510 |
Why?
| | Male | 84 | 2026 | 72315 | 0.510 |
Why?
| | Postoperative Complications | 7 | 2018 | 2919 | 0.510 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 108 | 0.510 |
Why?
| | Disease Management | 2 | 2018 | 645 | 0.510 |
Why?
| | Prospective Studies | 18 | 2025 | 7990 | 0.480 |
Why?
| | Benzimidazoles | 4 | 2024 | 190 | 0.470 |
Why?
| | Liver Failure | 3 | 2013 | 83 | 0.460 |
Why?
| | Glycine | 6 | 2002 | 187 | 0.450 |
Why?
| | Pediatrics | 5 | 2020 | 1114 | 0.440 |
Why?
| | Physical Examination | 2 | 2018 | 239 | 0.430 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2016 | 237 | 0.410 |
Why?
| | Biomarkers | 14 | 2026 | 4271 | 0.410 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2013 | 15 | 0.380 |
Why?
| | Autoantibodies | 3 | 2017 | 1501 | 0.380 |
Why?
| | Gastrointestinal Hemorrhage | 6 | 2022 | 136 | 0.380 |
Why?
| | Acetamides | 1 | 2013 | 37 | 0.370 |
Why?
| | Hepatitis B, Chronic | 3 | 2010 | 22 | 0.370 |
Why?
| | Colonoscopy | 1 | 2015 | 261 | 0.370 |
Why?
| | Quinolines | 4 | 2026 | 193 | 0.370 |
Why?
| | Infant, Newborn | 18 | 2018 | 6429 | 0.360 |
Why?
| | Gastrointestinal Microbiome | 2 | 2024 | 771 | 0.360 |
Why?
| | Carbamates | 2 | 2024 | 52 | 0.360 |
Why?
| | Sheep | 8 | 2002 | 880 | 0.360 |
Why?
| | Educational Measurement | 1 | 2015 | 326 | 0.350 |
Why?
| | Mutation | 4 | 2023 | 4089 | 0.350 |
Why?
| | Leukocyte L1 Antigen Complex | 2 | 2026 | 40 | 0.350 |
Why?
| | Carbon Dioxide | 2 | 2013 | 242 | 0.340 |
Why?
| | Gastrointestinal Diseases | 2 | 2026 | 216 | 0.340 |
Why?
| | Heart Defects, Congenital | 2 | 2018 | 914 | 0.330 |
Why?
| | Cohort Studies | 12 | 2023 | 5960 | 0.320 |
Why?
| | Folic Acid | 2 | 2002 | 199 | 0.320 |
Why?
| | Polyethylene Glycols | 9 | 2013 | 654 | 0.310 |
Why?
| | Blindness | 1 | 2010 | 52 | 0.310 |
Why?
| | Ultrasonography | 5 | 2020 | 770 | 0.310 |
Why?
| | Prognosis | 15 | 2020 | 4282 | 0.300 |
Why?
| | Retinal Diseases | 1 | 2010 | 101 | 0.300 |
Why?
| | Uridine Monophosphate | 2 | 2019 | 16 | 0.300 |
Why?
| | Optic Neuritis | 1 | 2009 | 44 | 0.290 |
Why?
| | Clinical Competence | 3 | 2020 | 1244 | 0.290 |
Why?
| | Uveitis | 1 | 2010 | 148 | 0.290 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 676 | 0.290 |
Why?
| | Fluorenes | 2 | 2019 | 46 | 0.290 |
Why?
| | Research | 2 | 2002 | 431 | 0.280 |
Why?
| | Esophagoscopy | 3 | 2018 | 221 | 0.280 |
Why?
| | Sofosbuvir | 3 | 2024 | 61 | 0.270 |
Why?
| | Recombinant Proteins | 12 | 2013 | 1370 | 0.270 |
Why?
| | Hepatitis C | 4 | 2012 | 254 | 0.270 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2363 | 0.260 |
Why?
| | ROC Curve | 3 | 2019 | 614 | 0.260 |
Why?
| | Prevalence | 5 | 2017 | 2834 | 0.260 |
Why?
| | Glycine Hydroxymethyltransferase | 4 | 2001 | 16 | 0.260 |
Why?
| | Severity of Illness Index | 10 | 2020 | 2925 | 0.250 |
Why?
| | Sulfonamides | 2 | 2021 | 580 | 0.250 |
Why?
| | Chemical and Drug Induced Liver Injury | 2 | 2026 | 139 | 0.240 |
Why?
| | Bilirubin | 6 | 2026 | 97 | 0.240 |
Why?
| | Canada | 4 | 2018 | 428 | 0.230 |
Why?
| | Immediate-Early Proteins | 1 | 2005 | 48 | 0.230 |
Why?
| | Cholestasis, Intrahepatic | 3 | 2003 | 29 | 0.230 |
Why?
| | Galactose | 2 | 2003 | 34 | 0.230 |
Why?
| | Young Adult | 13 | 2026 | 14105 | 0.230 |
Why?
| | Disease Progression | 6 | 2026 | 2847 | 0.220 |
Why?
| | Biliary Tract Diseases | 2 | 2002 | 33 | 0.220 |
Why?
| | Alagille Syndrome | 2 | 2022 | 29 | 0.220 |
Why?
| | Quality of Health Care | 1 | 2009 | 691 | 0.210 |
Why?
| | Retrospective Studies | 18 | 2026 | 17066 | 0.210 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2024 | 23 | 0.210 |
Why?
| | Lung Diseases | 2 | 2018 | 787 | 0.210 |
Why?
| | Transfusion Reaction | 1 | 2004 | 63 | 0.210 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 381 | 0.200 |
Why?
| | Ascites | 2 | 2015 | 49 | 0.200 |
Why?
| | Treatment Outcome | 20 | 2024 | 11679 | 0.200 |
Why?
| | Case-Control Studies | 8 | 2020 | 3604 | 0.190 |
Why?
| | Mass Screening | 2 | 2023 | 1347 | 0.190 |
Why?
| | Follow-Up Studies | 10 | 2022 | 5408 | 0.190 |
Why?
| | Platelet Activation | 1 | 2003 | 104 | 0.190 |
Why?
| | Placenta | 4 | 2010 | 780 | 0.180 |
Why?
| | Bone Density | 1 | 2026 | 482 | 0.180 |
Why?
| | Paracentesis | 1 | 2001 | 16 | 0.180 |
Why?
| | Choledochal Cyst | 3 | 2013 | 17 | 0.170 |
Why?
| | Hepatocytes | 1 | 2002 | 223 | 0.170 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 2 | 2006 | 219 | 0.170 |
Why?
| | Longitudinal Studies | 5 | 2026 | 2947 | 0.170 |
Why?
| | Herpesvirus 4, Human | 3 | 2013 | 176 | 0.170 |
Why?
| | Portoenterostomy, Hepatic | 4 | 2015 | 43 | 0.170 |
Why?
| | Quinoxalines | 1 | 2021 | 65 | 0.170 |
Why?
| | Menstruation | 1 | 2020 | 42 | 0.160 |
Why?
| | United States | 8 | 2020 | 15966 | 0.160 |
Why?
| | Transforming Growth Factor beta | 1 | 2003 | 479 | 0.160 |
Why?
| | Uracil | 1 | 2020 | 36 | 0.160 |
Why?
| | Registries | 5 | 2018 | 2385 | 0.160 |
Why?
| | Adult | 25 | 2026 | 40449 | 0.160 |
Why?
| | Risk Factors | 10 | 2018 | 10779 | 0.160 |
Why?
| | Insulin | 5 | 2025 | 2507 | 0.160 |
Why?
| | Cyclopropanes | 1 | 2020 | 83 | 0.160 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2020 | 18 | 0.160 |
Why?
| | Lactams, Macrocyclic | 1 | 2020 | 51 | 0.160 |
Why?
| | Bile Acids and Salts | 2 | 2016 | 164 | 0.160 |
Why?
| | Acute Disease | 3 | 2016 | 1030 | 0.150 |
Why?
| | Anilides | 1 | 2020 | 84 | 0.150 |
Why?
| | Ritonavir | 1 | 2020 | 75 | 0.150 |
Why?
| | Proline | 1 | 2020 | 83 | 0.150 |
Why?
| | Postoperative Care | 2 | 2019 | 288 | 0.150 |
Why?
| | Drug Therapy, Combination | 7 | 2020 | 1047 | 0.150 |
Why?
| | Biopsy | 8 | 2019 | 1075 | 0.150 |
Why?
| | Hepatitis, Chronic | 2 | 1995 | 5 | 0.150 |
Why?
| | Hepatic Encephalopathy | 5 | 2013 | 25 | 0.150 |
Why?
| | Carrier Proteins | 3 | 2016 | 737 | 0.140 |
Why?
| | Phosphoenolpyruvate Carboxykinase (GTP) | 4 | 1993 | 30 | 0.140 |
Why?
| | Neonatal Screening | 3 | 2016 | 178 | 0.140 |
Why?
| | Databases, Factual | 4 | 2015 | 1486 | 0.140 |
Why?
| | Common Bile Duct Diseases | 1 | 1998 | 3 | 0.140 |
Why?
| | Electrocoagulation | 1 | 2018 | 36 | 0.140 |
Why?
| | Dilatation | 1 | 2018 | 72 | 0.140 |
Why?
| | Fluoroscopy | 1 | 2018 | 176 | 0.140 |
Why?
| | Exercise Test | 2 | 2018 | 634 | 0.140 |
Why?
| | Pyruvic Acid | 2 | 2017 | 55 | 0.140 |
Why?
| | Epidermolysis Bullosa | 1 | 2018 | 68 | 0.130 |
Why?
| | Age Factors | 4 | 2017 | 3333 | 0.130 |
Why?
| | Survival Rate | 8 | 2019 | 2089 | 0.130 |
Why?
| | Graft Rejection | 2 | 2013 | 540 | 0.130 |
Why?
| | Logistic Models | 3 | 2017 | 2117 | 0.130 |
Why?
| | Trypsin Inhibitor, Kazal Pancreatic | 1 | 2016 | 6 | 0.120 |
Why?
| | Sustained Virologic Response | 3 | 2024 | 46 | 0.120 |
Why?
| | Lactic Acid | 2 | 2017 | 302 | 0.120 |
Why?
| | Trypsin | 1 | 2016 | 76 | 0.120 |
Why?
| | Mitochondrial Diseases | 1 | 2017 | 93 | 0.120 |
Why?
| | Growth Disorders | 2 | 2015 | 86 | 0.120 |
Why?
| | Zinc | 1 | 1999 | 295 | 0.120 |
Why?
| | Autoimmune Diseases | 3 | 2013 | 463 | 0.120 |
Why?
| | Fetus | 3 | 2000 | 803 | 0.120 |
Why?
| | Blood Glucose | 2 | 2025 | 2327 | 0.120 |
Why?
| | Statistics as Topic | 1 | 2016 | 284 | 0.110 |
Why?
| | Recurrence | 3 | 2016 | 1135 | 0.110 |
Why?
| | Lung Transplantation | 1 | 2019 | 338 | 0.110 |
Why?
| | Parenteral Nutrition, Total | 1 | 1995 | 30 | 0.110 |
Why?
| | Preoperative Care | 2 | 2019 | 379 | 0.110 |
Why?
| | Cells, Cultured | 8 | 2015 | 4154 | 0.110 |
Why?
| | Capsule Endoscopes | 1 | 2015 | 7 | 0.110 |
Why?
| | Fatty Liver | 2 | 2012 | 251 | 0.110 |
Why?
| | Kidney | 2 | 2001 | 1495 | 0.110 |
Why?
| | Hepatitis B | 1 | 1995 | 66 | 0.110 |
Why?
| | Incidence | 3 | 2018 | 2879 | 0.110 |
Why?
| | Glucokinase | 3 | 1991 | 15 | 0.110 |
Why?
| | Sensitivity and Specificity | 2 | 2018 | 1985 | 0.110 |
Why?
| | Permeability | 1 | 2015 | 168 | 0.110 |
Why?
| | RNA, Messenger | 5 | 2005 | 2832 | 0.110 |
Why?
| | Pseudomonas Infections | 2 | 2015 | 221 | 0.110 |
Why?
| | Prothrombin Time | 4 | 2012 | 33 | 0.110 |
Why?
| | Quality of Life | 4 | 2022 | 3185 | 0.100 |
Why?
| | Cysteine | 1 | 1995 | 210 | 0.100 |
Why?
| | Animals, Newborn | 2 | 2001 | 902 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 965 | 0.100 |
Why?
| | Cross-Sectional Studies | 4 | 2018 | 5868 | 0.100 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 62 | 0.100 |
Why?
| | Insulin-Like Growth Factor II | 1 | 1993 | 24 | 0.100 |
Why?
| | Hepatitis, Viral, Human | 2 | 2006 | 20 | 0.100 |
Why?
| | Curriculum | 1 | 2020 | 1059 | 0.100 |
Why?
| | Amino Acids | 2 | 1996 | 521 | 0.100 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 80 | 0.100 |
Why?
| | Lymphocyte Activation | 2 | 2015 | 1126 | 0.090 |
Why?
| | Risk Assessment | 4 | 2020 | 3671 | 0.090 |
Why?
| | Acetylcysteine | 1 | 2013 | 139 | 0.090 |
Why?
| | Professional Competence | 1 | 2013 | 98 | 0.090 |
Why?
| | Chronic Disease | 6 | 2010 | 1813 | 0.090 |
Why?
| | DNA, Viral | 4 | 2010 | 358 | 0.090 |
Why?
| | Decision Making | 1 | 2019 | 975 | 0.090 |
Why?
| | Diffuse Cerebral Sclerosis of Schilder | 1 | 1991 | 4 | 0.090 |
Why?
| | Glucose | 4 | 2002 | 1047 | 0.090 |
Why?
| | Lipid Metabolism | 1 | 1995 | 527 | 0.090 |
Why?
| | Cognition | 2 | 2011 | 1266 | 0.090 |
Why?
| | Algorithms | 1 | 2019 | 1837 | 0.090 |
Why?
| | Time Factors | 11 | 2019 | 7173 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2015 | 1129 | 0.080 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1993 | 319 | 0.080 |
Why?
| | United Kingdom | 2 | 2009 | 338 | 0.080 |
Why?
| | Behavior | 1 | 2011 | 91 | 0.080 |
Why?
| | Triiodothyronine | 1 | 1990 | 54 | 0.080 |
Why?
| | Embryonic and Fetal Development | 2 | 2001 | 93 | 0.080 |
Why?
| | Pregnancy | 9 | 2010 | 7190 | 0.080 |
Why?
| | Clinical Chemistry Tests | 1 | 2010 | 6 | 0.080 |
Why?
| | Animals | 18 | 2002 | 38058 | 0.080 |
Why?
| | Malabsorption Syndromes | 1 | 2010 | 16 | 0.080 |
Why?
| | Lauric Acids | 1 | 2010 | 9 | 0.080 |
Why?
| | Vitamin A Deficiency | 2 | 2005 | 26 | 0.080 |
Why?
| | Fetal Blood | 2 | 2010 | 342 | 0.080 |
Why?
| | Natriuretic Peptides | 1 | 2009 | 9 | 0.080 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2010 | 80 | 0.080 |
Why?
| | Up-Regulation | 1 | 2013 | 851 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2018 | 1173 | 0.080 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3409 | 0.080 |
Why?
| | Enzymes | 1 | 2010 | 65 | 0.080 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2009 | 23 | 0.080 |
Why?
| | Suture Techniques | 1 | 2010 | 131 | 0.080 |
Why?
| | Digestive System Surgical Procedures | 1 | 2010 | 109 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1539 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2015 | 917 | 0.070 |
Why?
| | Internship and Residency | 1 | 2020 | 1257 | 0.070 |
Why?
| | Genotype | 3 | 2024 | 1833 | 0.070 |
Why?
| | Optic Nerve | 1 | 2009 | 67 | 0.070 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2009 | 12 | 0.070 |
Why?
| | Roseolovirus Infections | 1 | 2009 | 8 | 0.070 |
Why?
| | Protozoan Infections | 1 | 1989 | 11 | 0.070 |
Why?
| | Amino Acid Oxidoreductases | 2 | 2001 | 19 | 0.070 |
Why?
| | Transferases | 2 | 2001 | 27 | 0.070 |
Why?
| | Agammaglobulinemia | 1 | 2009 | 36 | 0.070 |
Why?
| | Interferon-gamma | 2 | 2015 | 784 | 0.070 |
Why?
| | Multienzyme Complexes | 2 | 2001 | 67 | 0.070 |
Why?
| | Vitamin E | 6 | 2005 | 121 | 0.070 |
Why?
| | Biliary Tract Surgical Procedures | 2 | 2011 | 28 | 0.070 |
Why?
| | Hospitalization | 2 | 2016 | 2433 | 0.070 |
Why?
| | Body Composition | 1 | 2012 | 706 | 0.070 |
Why?
| | Gastroenteritis | 1 | 1989 | 63 | 0.070 |
Why?
| | Dietary Fats | 1 | 2010 | 314 | 0.070 |
Why?
| | Societies, Medical | 3 | 2013 | 887 | 0.070 |
Why?
| | Lung | 2 | 2012 | 4109 | 0.070 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1989 | 235 | 0.060 |
Why?
| | Ischemia | 1 | 2010 | 421 | 0.060 |
Why?
| | Abdomen, Acute | 1 | 2006 | 21 | 0.060 |
Why?
| | Bile Duct Diseases | 1 | 2006 | 13 | 0.060 |
Why?
| | Fatty Acids | 1 | 2010 | 450 | 0.060 |
Why?
| | Survival Analysis | 5 | 2013 | 1382 | 0.060 |
Why?
| | Vitamin A | 2 | 2005 | 59 | 0.060 |
Why?
| | Child Behavior | 1 | 2009 | 236 | 0.060 |
Why?
| | Hemophilia A | 1 | 1989 | 147 | 0.060 |
Why?
| | Research Design | 1 | 2012 | 1135 | 0.060 |
Why?
| | Interleukin-12 | 1 | 2006 | 117 | 0.060 |
Why?
| | Isoquinolines | 1 | 2026 | 44 | 0.060 |
Why?
| | Hypertension, Pulmonary | 2 | 2009 | 1980 | 0.060 |
Why?
| | Biliary Tract | 1 | 2005 | 14 | 0.060 |
Why?
| | Laparoscopy | 1 | 2010 | 475 | 0.060 |
Why?
| | Connective Tissue Growth Factor | 1 | 2005 | 27 | 0.060 |
Why?
| | Copper | 2 | 1998 | 113 | 0.060 |
Why?
| | Influenza A virus | 1 | 2006 | 113 | 0.060 |
Why?
| | Emotions | 1 | 2011 | 578 | 0.060 |
Why?
| | Autopsy | 1 | 2005 | 94 | 0.060 |
Why?
| | Glycogen Storage Disease Type IV | 1 | 2005 | 4 | 0.060 |
Why?
| | 1,4-alpha-Glucan Branching Enzyme | 1 | 2005 | 4 | 0.060 |
Why?
| | Bile | 1 | 2005 | 26 | 0.060 |
Why?
| | In Situ Hybridization | 1 | 2005 | 319 | 0.060 |
Why?
| | Culture Media | 3 | 1996 | 161 | 0.060 |
Why?
| | Absorptiometry, Photon | 1 | 2026 | 276 | 0.050 |
Why?
| | Predictive Value of Tests | 4 | 2013 | 2115 | 0.050 |
Why?
| | Carnitine | 1 | 2005 | 90 | 0.050 |
Why?
| | Endoscopy | 2 | 1998 | 316 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2013 | 1982 | 0.050 |
Why?
| | Acetyl-CoA Carboxylase | 3 | 1995 | 32 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2010 | 846 | 0.050 |
Why?
| | Drug Resistance, Viral | 2 | 2018 | 122 | 0.050 |
Why?
| | Inflammation | 2 | 2026 | 2878 | 0.050 |
Why?
| | Benzopyrans | 1 | 2024 | 30 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2025 | 361 | 0.050 |
Why?
| | Mothers | 1 | 2010 | 775 | 0.050 |
Why?
| | Glucagon | 3 | 2002 | 112 | 0.050 |
Why?
| | Disease Transmission, Infectious | 1 | 2004 | 69 | 0.050 |
Why?
| | Lupus Erythematosus, Cutaneous | 1 | 2003 | 7 | 0.050 |
Why?
| | Respiratory Function Tests | 2 | 2018 | 547 | 0.050 |
Why?
| | Kinetics | 3 | 2000 | 1627 | 0.050 |
Why?
| | Platelet Factor 4 | 1 | 2003 | 36 | 0.050 |
Why?
| | Endoglin | 1 | 2022 | 19 | 0.050 |
Why?
| | Blood Coagulation Tests | 1 | 2003 | 70 | 0.050 |
Why?
| | Pancreatic Elastase | 1 | 2022 | 55 | 0.050 |
Why?
| | Carbon Radioisotopes | 2 | 2000 | 29 | 0.050 |
Why?
| | Blood Donors | 1 | 2004 | 143 | 0.050 |
Why?
| | Pyrroles | 1 | 2024 | 217 | 0.050 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2022 | 25 | 0.050 |
Why?
| | Bromodeoxyuridine | 1 | 2002 | 79 | 0.050 |
Why?
| | Niemann-Pick Diseases | 1 | 2002 | 8 | 0.050 |
Why?
| | Analysis of Variance | 2 | 2015 | 1306 | 0.050 |
Why?
| | Anastomosis, Surgical | 2 | 2011 | 157 | 0.050 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2004 | 193 | 0.050 |
Why?
| | Dysbiosis | 1 | 2024 | 187 | 0.050 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2003 | 178 | 0.050 |
Why?
| | International Normalized Ratio | 2 | 2012 | 49 | 0.050 |
Why?
| | Enzyme Induction | 2 | 1993 | 88 | 0.050 |
Why?
| | Somatostatin | 1 | 2002 | 51 | 0.040 |
Why?
| | Umbilical Veins | 1 | 2002 | 59 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 1907 | 0.040 |
Why?
| | Pilot Projects | 4 | 2006 | 1886 | 0.040 |
Why?
| | Plasma Volume | 1 | 2001 | 20 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2026 | 1489 | 0.040 |
Why?
| | Punctures | 1 | 2001 | 40 | 0.040 |
Why?
| | Weaning | 4 | 1995 | 46 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2022 | 271 | 0.040 |
Why?
| | Oxidoreductases Acting on CH-NH Group Donors | 1 | 2001 | 3 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2026 | 488 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2005 | 1716 | 0.040 |
Why?
| | 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2001 | 18 | 0.040 |
Why?
| | Cholangitis | 1 | 2001 | 23 | 0.040 |
Why?
| | Constipation | 1 | 2022 | 98 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2021 | 69 | 0.040 |
Why?
| | Tetrahydrofolates | 1 | 2001 | 16 | 0.040 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2002 | 106 | 0.040 |
Why?
| | Needles | 1 | 2001 | 62 | 0.040 |
Why?
| | Patient Selection | 2 | 2019 | 719 | 0.040 |
Why?
| | Cardiomyopathies | 1 | 2005 | 338 | 0.040 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2001 | 35 | 0.040 |
Why?
| | Chlorides | 1 | 2022 | 142 | 0.040 |
Why?
| | Leucovorin | 1 | 2001 | 101 | 0.040 |
Why?
| | Health Status | 2 | 2022 | 836 | 0.040 |
Why?
| | RNA, Viral | 2 | 2010 | 688 | 0.040 |
Why?
| | North America | 1 | 2002 | 310 | 0.040 |
Why?
| | Catheterization | 1 | 2001 | 183 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2003 | 636 | 0.040 |
Why?
| | 2-Naphthylamine | 1 | 2020 | 6 | 0.040 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2020 | 12 | 0.040 |
Why?
| | Influenza, Human | 1 | 2006 | 616 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 129 | 0.040 |
Why?
| | Tablets | 1 | 2020 | 41 | 0.040 |
Why?
| | Drainage | 1 | 2001 | 185 | 0.040 |
Why?
| | Stress, Psychological | 1 | 2009 | 1152 | 0.040 |
Why?
| | Intestinal Absorption | 2 | 2010 | 103 | 0.040 |
Why?
| | Hepatitis B virus | 2 | 2010 | 33 | 0.040 |
Why?
| | Nutritional Status | 2 | 2015 | 354 | 0.040 |
Why?
| | Phosphoglycerate Dehydrogenase | 1 | 1999 | 6 | 0.040 |
Why?
| | Gestational Age | 2 | 2002 | 975 | 0.040 |
Why?
| | Carbohydrate Dehydrogenases | 1 | 1999 | 11 | 0.040 |
Why?
| | Valine | 1 | 2020 | 80 | 0.040 |
Why?
| | Animals, Suckling | 3 | 1995 | 5 | 0.040 |
Why?
| | Caregivers | 1 | 2009 | 1049 | 0.040 |
Why?
| | Rabbits | 1 | 2001 | 648 | 0.040 |
Why?
| | Binding, Competitive | 1 | 2000 | 193 | 0.040 |
Why?
| | Transaminases | 1 | 1999 | 22 | 0.040 |
Why?
| | Accreditation | 1 | 2020 | 101 | 0.040 |
Why?
| | Blood Platelets | 1 | 2003 | 400 | 0.040 |
Why?
| | Syndrome | 2 | 2009 | 380 | 0.040 |
Why?
| | Competency-Based Education | 1 | 2020 | 79 | 0.040 |
Why?
| | Leucine | 1 | 2000 | 116 | 0.040 |
Why?
| | Pruritus | 1 | 1999 | 59 | 0.040 |
Why?
| | Safety | 1 | 2001 | 356 | 0.040 |
Why?
| | Rats | 6 | 1995 | 5597 | 0.040 |
Why?
| | Rifampin | 1 | 1999 | 82 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 1991 | 269 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2005 | 1125 | 0.040 |
Why?
| | Hypersplenism | 1 | 1998 | 9 | 0.040 |
Why?
| | Heart | 1 | 2003 | 636 | 0.040 |
Why?
| | Isoenzymes | 1 | 1999 | 299 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2023 | 1095 | 0.040 |
Why?
| | Biological Transport | 1 | 2000 | 417 | 0.040 |
Why?
| | Referral and Consultation | 2 | 2019 | 851 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2001 | 338 | 0.040 |
Why?
| | Duodenoscopy | 1 | 1998 | 8 | 0.040 |
Why?
| | Medicine | 1 | 2020 | 125 | 0.040 |
Why?
| | Pemoline | 1 | 1998 | 4 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2005 | 1782 | 0.040 |
Why?
| | Lipids | 4 | 2002 | 710 | 0.030 |
Why?
| | Rats, Inbred Strains | 4 | 1990 | 321 | 0.030 |
Why?
| | Sphincterotomy, Endoscopic | 1 | 1998 | 29 | 0.030 |
Why?
| | Genes, Viral | 1 | 1998 | 90 | 0.030 |
Why?
| | Gluconeogenesis | 2 | 2002 | 83 | 0.030 |
Why?
| | Reoviridae | 1 | 1998 | 38 | 0.030 |
Why?
| | Serum Albumin | 1 | 1999 | 147 | 0.030 |
Why?
| | Gallstones | 1 | 1998 | 35 | 0.030 |
Why?
| | Technetium Tc 99m Disofenin | 1 | 1998 | 3 | 0.030 |
Why?
| | Age Distribution | 1 | 2019 | 403 | 0.030 |
Why?
| | Medical History Taking | 1 | 2018 | 117 | 0.030 |
Why?
| | Postoperative Period | 1 | 1999 | 354 | 0.030 |
Why?
| | Reoviridae Infections | 1 | 1998 | 55 | 0.030 |
Why?
| | Pancreatic Diseases | 1 | 1998 | 66 | 0.030 |
Why?
| | Half-Life | 1 | 1998 | 151 | 0.030 |
Why?
| | Manganese | 1 | 1998 | 55 | 0.030 |
Why?
| | Hemodynamics | 1 | 2003 | 1121 | 0.030 |
Why?
| | Pancreas Transplantation | 1 | 2017 | 69 | 0.030 |
Why?
| | Caffeine | 1 | 1998 | 74 | 0.030 |
Why?
| | Reference Values | 1 | 1999 | 797 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 66 | 0.030 |
Why?
| | Creatinine | 1 | 1999 | 506 | 0.030 |
Why?
| | Ammonia | 2 | 2008 | 65 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2019 | 243 | 0.030 |
Why?
| | Esophagus | 1 | 2018 | 261 | 0.030 |
Why?
| | Injections, Subcutaneous | 2 | 2006 | 164 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2010 | 779 | 0.030 |
Why?
| | Central Nervous System Stimulants | 1 | 1998 | 185 | 0.030 |
Why?
| | Embolization, Therapeutic | 1 | 1998 | 242 | 0.030 |
Why?
| | Fellowships and Scholarships | 1 | 2020 | 357 | 0.030 |
Why?
| | Hypoalbuminemia | 1 | 2015 | 28 | 0.030 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2015 | 32 | 0.030 |
Why?
| | CHO Cells | 1 | 1996 | 171 | 0.030 |
Why?
| | Cricetinae | 1 | 1996 | 303 | 0.030 |
Why?
| | Food, Fortified | 1 | 1995 | 44 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 1998 | 601 | 0.030 |
Why?
| | Radiography | 1 | 1998 | 844 | 0.030 |
Why?
| | Cytosol | 1 | 1996 | 227 | 0.030 |
Why?
| | T-Box Domain Proteins | 1 | 2015 | 106 | 0.030 |
Why?
| | Body Mass Index | 2 | 2015 | 2438 | 0.030 |
Why?
| | Solubility | 2 | 2013 | 242 | 0.030 |
Why?
| | Glycerol | 1 | 1995 | 90 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2020 | 557 | 0.030 |
Why?
| | Hepatolenticular Degeneration | 1 | 1994 | 15 | 0.030 |
Why?
| | Transcription, Genetic | 2 | 1999 | 1496 | 0.030 |
Why?
| | Remission Induction | 1 | 1995 | 307 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 1995 | 427 | 0.030 |
Why?
| | Receptors, Immunologic | 1 | 2015 | 206 | 0.030 |
Why?
| | Ileum | 1 | 1995 | 111 | 0.030 |
Why?
| | Mitochondria, Liver | 1 | 1994 | 70 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2015 | 437 | 0.030 |
Why?
| | Random Allocation | 1 | 1995 | 363 | 0.030 |
Why?
| | Brain | 2 | 2001 | 2933 | 0.030 |
Why?
| | Echocardiography | 2 | 2009 | 652 | 0.030 |
Why?
| | Oxidants | 1 | 1994 | 103 | 0.030 |
Why?
| | Immunosuppressive Agents | 3 | 2007 | 846 | 0.030 |
Why?
| | Lipid Peroxidation | 2 | 1994 | 160 | 0.030 |
Why?
| | Choline | 1 | 1995 | 136 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1325 | 0.030 |
Why?
| | Vitamin E Deficiency | 2 | 1991 | 42 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2013 | 62 | 0.030 |
Why?
| | Prednisone | 1 | 1994 | 221 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2015 | 264 | 0.030 |
Why?
| | Cyclosporine | 1 | 1994 | 265 | 0.020 |
Why?
| | Thymidine | 1 | 1993 | 60 | 0.020 |
Why?
| | Lactates | 1 | 1993 | 83 | 0.020 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2013 | 10 | 0.020 |
Why?
| | Fatty Acid Synthases | 2 | 1990 | 23 | 0.020 |
Why?
| | Free Radical Scavengers | 1 | 2013 | 82 | 0.020 |
Why?
| | Biomarkers, Pharmacological | 1 | 2012 | 26 | 0.020 |
Why?
| | Colon | 1 | 1995 | 304 | 0.020 |
Why?
| | Pseudomonas aeruginosa | 1 | 2015 | 356 | 0.020 |
Why?
| | Polymerase Chain Reaction | 3 | 2002 | 1054 | 0.020 |
Why?
| | Eating | 2 | 2012 | 389 | 0.020 |
Why?
| | Cell Separation | 1 | 1993 | 307 | 0.020 |
Why?
| | Signal Transduction | 1 | 2005 | 5226 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 423 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1173 | 0.020 |
Why?
| | Vitamins | 2 | 1991 | 178 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2013 | 322 | 0.020 |
Why?
| | Aging | 2 | 2001 | 1966 | 0.020 |
Why?
| | Cell Division | 1 | 1993 | 766 | 0.020 |
Why?
| | Cyclosporins | 1 | 1991 | 71 | 0.020 |
Why?
| | Hemochromatosis | 1 | 2011 | 9 | 0.020 |
Why?
| | Hyperbilirubinemia | 1 | 2011 | 11 | 0.020 |
Why?
| | Vital Capacity | 1 | 2012 | 290 | 0.020 |
Why?
| | Choledochostomy | 1 | 2011 | 10 | 0.020 |
Why?
| | Body Height | 1 | 2012 | 202 | 0.020 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2011 | 26 | 0.020 |
Why?
| | Stimulation, Chemical | 1 | 1990 | 53 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1560 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1356 | 0.020 |
Why?
| | Status Epilepticus | 1 | 1991 | 56 | 0.020 |
Why?
| | Hepatitis B Surface Antigens | 1 | 2010 | 17 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2012 | 449 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 2112 | 0.020 |
Why?
| | Risk | 2 | 2005 | 911 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3863 | 0.020 |
Why?
| | Decidua | 1 | 2010 | 22 | 0.020 |
Why?
| | Prader-Willi Syndrome | 1 | 2010 | 31 | 0.020 |
Why?
| | Rectal Prolapse | 1 | 2010 | 24 | 0.020 |
Why?
| | Lamivudine | 1 | 2010 | 65 | 0.020 |
Why?
| | Enzyme Therapy | 1 | 2010 | 4 | 0.020 |
Why?
| | Herpes Simplex | 1 | 2011 | 98 | 0.020 |
Why?
| | Organophosphonates | 1 | 2010 | 97 | 0.020 |
Why?
| | Natural Killer T-Cells | 1 | 2010 | 67 | 0.020 |
Why?
| | Ligases | 1 | 1990 | 37 | 0.020 |
Why?
| | Neutropenia | 1 | 2010 | 155 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 2013 | 467 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 1995 | 2527 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 6048 | 0.020 |
Why?
| | Hepatitis B Vaccines | 1 | 2009 | 43 | 0.020 |
Why?
| | Legal Guardians | 1 | 2009 | 10 | 0.020 |
Why?
| | Herpesvirus 7, Human | 1 | 2009 | 6 | 0.020 |
Why?
| | Hormones | 1 | 1990 | 134 | 0.020 |
Why?
| | Rectum | 1 | 2010 | 180 | 0.020 |
Why?
| | Mitochondria | 1 | 1996 | 984 | 0.020 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2010 | 192 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2009 | 62 | 0.020 |
Why?
| | Vitamin D Deficiency | 1 | 1991 | 186 | 0.020 |
Why?
| | Opportunistic Infections | 1 | 1989 | 45 | 0.020 |
Why?
| | Living Donors | 1 | 2011 | 280 | 0.020 |
Why?
| | Gene Expression | 1 | 1993 | 1490 | 0.020 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2009 | 126 | 0.020 |
Why?
| | Hypoglycemia | 1 | 1993 | 477 | 0.020 |
Why?
| | Body Weight | 1 | 2012 | 976 | 0.020 |
Why?
| | Adenine | 1 | 2010 | 339 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 2029 | 0.020 |
Why?
| | Pancreas | 1 | 2010 | 341 | 0.020 |
Why?
| | Fibrosis | 1 | 2009 | 548 | 0.020 |
Why?
| | Rupture, Spontaneous | 1 | 2006 | 15 | 0.020 |
Why?
| | Probability | 1 | 2007 | 310 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2010 | 499 | 0.020 |
Why?
| | Treatment Failure | 1 | 2007 | 365 | 0.020 |
Why?
| | Middle Aged | 5 | 2019 | 35875 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1053 | 0.020 |
Why?
| | DNA | 1 | 1993 | 1463 | 0.020 |
Why?
| | Interferon-beta | 1 | 2006 | 92 | 0.020 |
Why?
| | Glucocorticoids | 1 | 1990 | 535 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1990 | 2027 | 0.010 |
Why?
| | Retinol-Binding Proteins | 1 | 2005 | 17 | 0.010 |
Why?
| | Diterpenes | 1 | 2005 | 26 | 0.010 |
Why?
| | Skin Physiological Phenomena | 1 | 1985 | 24 | 0.010 |
Why?
| | Dietary Supplements | 1 | 2010 | 576 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2006 | 570 | 0.010 |
Why?
| | Amylopectin | 1 | 2005 | 5 | 0.010 |
Why?
| | Esterification | 1 | 2005 | 9 | 0.010 |
Why?
| | Cause of Death | 1 | 2007 | 471 | 0.010 |
Why?
| | Electrodes | 1 | 1985 | 114 | 0.010 |
Why?
| | Adipose Tissue | 1 | 1990 | 652 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2005 | 167 | 0.010 |
Why?
| | Reoperation | 1 | 2007 | 630 | 0.010 |
Why?
| | Dry Eye Syndromes | 1 | 2005 | 56 | 0.010 |
Why?
| | Viral Load | 1 | 2006 | 526 | 0.010 |
Why?
| | Oxygen Consumption | 2 | 2002 | 724 | 0.010 |
Why?
| | Leukocytes, Mononuclear | 1 | 2006 | 573 | 0.010 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2003 | 19 | 0.010 |
Why?
| | Antibodies, Antinuclear | 1 | 2003 | 62 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1985 | 289 | 0.010 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2003 | 131 | 0.010 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2003 | 199 | 0.010 |
Why?
| | Needs Assessment | 1 | 2006 | 404 | 0.010 |
Why?
| | Administration, Oral | 1 | 2005 | 847 | 0.010 |
Why?
| | Splenomegaly | 1 | 2002 | 14 | 0.010 |
Why?
| | Surgical Procedures, Operative | 1 | 1985 | 270 | 0.010 |
Why?
| | Ornithine | 1 | 2002 | 28 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 1199 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2002 | 415 | 0.010 |
Why?
| | Medical Records | 1 | 2002 | 187 | 0.010 |
Why?
| | Influenza Vaccines | 1 | 2006 | 529 | 0.010 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2005 | 392 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 662 | 0.010 |
Why?
| | Glutamine | 1 | 2002 | 109 | 0.010 |
Why?
| | Cardiac Catheterization | 1 | 2005 | 560 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 851 | 0.010 |
Why?
| | Alanine | 1 | 2002 | 171 | 0.010 |
Why?
| | Vaccination | 1 | 2009 | 1423 | 0.010 |
Why?
| | Arginine | 1 | 2002 | 262 | 0.010 |
Why?
| | DNA Probes | 2 | 1990 | 59 | 0.010 |
Why?
| | Parents | 1 | 2009 | 1403 | 0.010 |
Why?
| | Fibroblasts | 1 | 2005 | 1034 | 0.010 |
Why?
| | gamma-Globulins | 1 | 1998 | 14 | 0.010 |
Why?
| | Jaundice | 1 | 1998 | 10 | 0.010 |
Why?
| | Esophagoscopes | 1 | 1996 | 4 | 0.010 |
Why?
| | Endoscopes | 1 | 1996 | 17 | 0.010 |
Why?
| | Ligation | 1 | 1996 | 92 | 0.010 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1995 | 28 | 0.010 |
Why?
| | Ulcer | 1 | 1995 | 37 | 0.010 |
Why?
| | Necrosis | 1 | 1995 | 244 | 0.010 |
Why?
| | Azathioprine | 1 | 1994 | 49 | 0.010 |
Why?
| | Microsomes, Liver | 1 | 1994 | 85 | 0.010 |
Why?
| | Diarrhea | 1 | 1995 | 192 | 0.010 |
Why?
| | Drug Resistance | 1 | 1994 | 153 | 0.010 |
Why?
| | Fever | 1 | 1995 | 311 | 0.010 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 1998 | 428 | 0.010 |
Why?
| | Dogs | 1 | 1994 | 437 | 0.010 |
Why?
| | Linear Models | 1 | 1995 | 854 | 0.010 |
Why?
| | Acetaminophen | 1 | 1995 | 264 | 0.010 |
Why?
| | Length of Stay | 1 | 1998 | 1337 | 0.010 |
Why?
| | Regression Analysis | 1 | 1994 | 1003 | 0.010 |
Why?
| | Pancreatin | 1 | 1991 | 6 | 0.010 |
Why?
| | Taurocholic Acid | 1 | 1990 | 8 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 1990 | 69 | 0.010 |
Why?
| | Hydroxycholecalciferols | 1 | 1989 | 3 | 0.000 |
Why?
| | Infant Nutrition Disorders | 1 | 1989 | 10 | 0.000 |
Why?
| | Vitamin K | 1 | 1989 | 45 | 0.000 |
Why?
| | Cell Survival | 1 | 1990 | 1098 | 0.000 |
Why?
| | Energy Intake | 1 | 1990 | 499 | 0.000 |
Why?
| | Iridium | 1 | 1985 | 7 | 0.000 |
Why?
| | Partial Pressure | 1 | 1985 | 31 | 0.000 |
Why?
| | Skin Temperature | 1 | 1985 | 36 | 0.000 |
Why?
| | Colorado | 1 | 1995 | 4564 | 0.000 |
Why?
| | Aged | 2 | 1994 | 25913 | 0.000 |
Why?
|
|
Narkewicz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|